Pharmacol

Pharmacol is a South Korean biotechnology company focused on developing first-in-class therapeutics for metabolic and degenerative diseases by targeting mitochondrial dysfunction. Founded in 2018 as a spin-off from Yonsei University, the company leverages its proprietary mitochondrial screening platform to identify small molecule candidates that regulate mitochondrial calcium homeostasis. Its lead program, PHM-001, is a mitochondrial calcium uniporter (MCU) inhibitor currently in Phase 1 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). The company's broader pipeline includes preclinical assets targeting obesity, type 2 diabetes, and chronic kidney disease. Pharmacol aims to address significant unmet medical needs in the metabolic space through its unique focus on mitochondrial medicine.